Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Dexcom (DXCM) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDXCM

Closing price · Nov 19, 2026 $79.36 -3.8% on the day · +32.9% over 12 months 52-week range $57.56 – $92.34
Get DXCM alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling8last 12 months
Reported sales$12.7M33 of 33 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Past insider buys here: 1 of 1 beat the S&P 500 over the next 90 days (small sample). See each one ↓

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 28, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Michael Jon Brown, General Counsel sold 1,700 shares at $83.46 ($142K).

Trade date
Nov 16, 2026
Disclosed to the SEC
Nov 18, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All DXCM insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

DXCM insider transactions (Form 4)

Open-market purchases and sales. 57 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 18SEC Michael Jon BrownGeneral Counsel Sell Plan 1,70095,034 held (−2%) $83.46 $142K -4.9% —
Oct 28SEC Sadie SternEvp Chief People & Culture Off Sell Plan 2,565120,913 held (−2%) $78.62 $202K +0.9% —
Oct 19SEC Michael Jon BrownGeneral Counsel Sell Plan 1,70098,185 held (−2%) $85.48 $145K -7.2% —
Sep 30SEC Sadie SternEvp Chief People & Culture Off Sell Plan 2,565123,478 held (−2%) $86.15 $221K -7.9% —
Sep 16SEC Nicholas AugustinosDirector Sell Plan 6,53929,293 held (−18%) $84.04 $550K -5.6% —
Sep 16SEC Michael Jon BrownGeneral Counsel Sell Plan 1,70099,885 held (−2%) $84.04 $143K -5.6% —
Sep 16SEC Nicholas AugustinosDirector Sell Plan 1,55035,832 held (−4%) $84.02 $130K -5.5% —
Sep 14SEC Jereme M. SylvainEvp, Chief Financal Officer Sell Plan 3,638146,828 held (−2%) $83.27 $303K -4.7% —
Aug 28SEC Sadie SternEvp Chief People & Culture Off Sell Plan 2,565126,043 held (−2%) $88.37 $227K -10.2% —
Aug 24SEC Kevin R. SayerChair Sell Plan 19,308309,662 held (−6%) $89.71 $1.7M -11.5% —
Aug 24SEC Kevin R. SayerChair Sell Plan 7,351302,311 held (−2%) $90.78 $667K -12.6% —
Aug 24SEC Kevin R. SayerChair Sell Plan 97302,214 held (−0%) $91.41 $9K -13.2% —
Aug 17SEC Michael Jon BrownGeneral Counsel Sell Plan 1,700102,953 held (−2%) $91.93 $156K -13.7% —
Aug 13SEC Bridgette P. HellerDirector Sell Plan 1,01229,570 held (−3%) $88.29 $89K -10.1% —
Aug 4SEC Mark G. FolettaDirector Sell Plan 2,00048,852 held (−4%) $85.32 $171K -7.0% —
Aug 4SEC Mark G. FolettaDirector Sell Plan 2,00050,852 held (−4%) $80.00 $160K -0.8% —
Jul 21SEC Kevin R. SayerChair Sell Plan 26,756328,970 held (−8%) $76.32 $2.0M +4.0% —
Jul 16SEC Michael Jon BrownGeneral Counsel Sell Plan 1,700104,653 held (−2%) $74.42 $127K +6.6% —
Jul 7SEC Kevin R. SayerChair Sell Plan 26,756355,726 held (−7%) $72.00 $1.9M +10.2% —
Jun 17SEC Mark G. FolettaDirector Sell Plan 3,80153,051 held (−7%) $74.10 $282K +7.1% —
Jun 17SEC Michael Jon BrownGeneral Counsel Sell Plan 1,700106,353 held (−2%) $75.55 $128K +5.0% —
Jun 17SEC Mark G. FolettaDirector Sell Plan 19952,852 held (−0%) $74.82 $15K +6.1% —
Jun 5SEC Jon ColemanEvp, Chief Commercial Officer Sell Plan 4,91195,450 held (−5%) $74.13 $364K +7.1% —
Jun 5SEC Jon ColemanEvp, Chief Commercial Officer Sell Plan 4,912100,361 held (−5%) $73.00 $359K +8.7% —
May 26SEC Kevin R. SayerChair Sell Plan 26,759382,482 held (−7%) $72.00 $1.9M +10.2% —
May 19SEC Michael Jon BrownGeneral Counsel Sell Plan 1,700109,504 held (−2%) $59.91 $102K +32.5% —
May 14SEC Bridgette P. HellerDirector Sell Plan 1,01225,007 held (−4%) $60.01 $61K +32.2% —
Apr 16SEC Michael Jon BrownGeneral Counsel Sell Plan 1,700111,204 held (−2%) $63.04 $107K +25.9% —
Mar 18SEC Michael Jon BrownGeneral Counsel Sell Plan 1,700112,904 held (−1%) $64.85 $110K +22.4% —
Feb 17SEC Bridgette P. HellerDirector Sell Plan 1,01226,019 held (−4%) $68.01 $69K +16.7% —
Nov 17SEC Richard Alexander CollinsDirector Sell Plan 2,90635,088 held (−8%) $59.05 $172K +34.4% —
Nov 12SEC Bridgette P. HellerDirector Sell Plan 1,01227,031 held (−4%) $58.07 $59K +36.7% —
Nov 10SEC Jacob Steven LeachCOO, PresidentFirst buy Buy 15,700329,197 held (+5%) $54.98 $863K +44.4% —
Nov 10SEC Richard Alexander CollinsDirector Sell Plan 3,94837,994 held (−9%) $55.17 $218K +43.8% —
Nov 10SEC Jacob Steven LeachCOO, PresidentFirst buy Buy 2,500331,697 held (+1%) $55.43 $139K +43.2% —
Historical context

Similar past setups: not applicable. DXCM has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with DXCM in the Research Lab

Pre-set to DXCM's latest insider buy of $10K or more (Nov 10, 2025: Jacob Steven Leach, $1.0M). Tap to change anything.

All tools →

Share price and insider trades

DXCM closeInsider buyInsider sale
406080100DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-12EEarnings release filed 2026-02-12EEarnings release filed 2026-04-30EEarnings release filed 2026-07-30EEarnings release filed 2026-10-29Sold $60,730 on 2026-05-12 · Bridgette P. HellerSold $68,826 on 2026-02-12 · Bridgette P. HellerSold $89,349 on 2026-08-12 · Bridgette P. HellerSold $101,847 on 2026-05-15 · Michael Jon BrownSold $107,168 on 2026-04-15 · Michael Jon BrownSold $110,245 on 2026-03-16 · Michael Jon BrownSold $126,514 on 2026-07-15 · Michael Jon BrownSold $130,231 on 2026-09-14 · Nicholas AugustinosSold $141,882 on 2026-11-16 · Michael Jon BrownSold $145,316 on 2026-10-15 · Michael Jon BrownSold $156,281 on 2026-08-14 · Michael Jon BrownSold $160,000 on 2026-07-31 · Mark G. FolettaSold $170,640 on 2026-08-03 · Mark G. FolettaSold $201,660 on 2026-10-27 · Sadie SternSold $220,975 on 2026-09-28 · Sadie SternSold $226,669 on 2026-08-27 · Sadie SternSold $302,936 on 2026-09-10 · Jereme M. SylvainSold $358,576 on 2026-06-03 · Jon ColemanSold $364,052 on 2026-06-04 · Jon ColemanSold $424,975 on 2026-06-15 · Mark G. Foletta, Michael Jon BrownSold $692,406 on 2026-09-15 · Michael Jon Brown, Nicholas AugustinosSold $1,926,432 on 2026-07-06 · Kevin R. SayerSold $1,926,648 on 2026-05-21 · Kevin R. SayerSold $2,041,999 on 2026-07-20 · Kevin R. SayerSold $2,408,242 on 2026-08-20 · Kevin R. Sayer
Bought, 12 months$0
Sold, 12 months$12.7M
Insiders buying0
Insiders selling8

Dexcom insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $12.7M of DXCM stock on the open market; P/E 37.6 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

DXCM insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $1.0M bought (2 trades)$1.0MQ4 2025: $448K sold (3 trades)Q4 2025Q1 2026: $179K sold (2 trades)Q1 2026Q2 2026: $3.3M sold (9 trades)Q2 2026Q3 2026: $8.7M sold (16 trades)Q3 2026Q4 2026: $489K sold (3 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$489K3
Q3 2026—0$8.7M16
Q2 2026—0$3.3M9
Q1 2026—0$179K2
Q4 2025$1.0M2$448K3

Valuation, profit and volume

P/E (trailing)37.6Sector median 25.0
Volume vs. 50-day0.8×Last 5 sessions
Insiders' paper profit+$443KOn all tracked purchases +44.2%

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Dexcom insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $12.7M. 33 of 33 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

DXCM earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 29, 2026 -7.6% Sold $347K +4.7%S&P -2.1% pending
Jul 30, 2026 +1.4% Sold $4.1M +11.1%S&P +2.4% +8.8%
Apr 30, 2026 -8.6% Sold $107K +6.6%S&P +1.3% +20.2%
Feb 12, 2026 -7.5% None +2.7%S&P -1.5% -8.3%
Jan 12, 2026 -0.0% None +4.2%S&P -0.0% -7.4%
Oct 30, 2025 +3.0% None -14.6%S&P -0.8% +9.0%
Jul 30, 2025 +4.7% None -9.6%S&P -0.5% -6.7%
May 1, 2025 +3.1% None +14.3%S&P +2.2% +5.1%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

DXCM short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 40% of volume sold short2026-08-27: 40% of volume sold short2026-08-28: 46% of volume sold short2026-08-31: 70% of volume sold short2026-09-01: 60% of volume sold short2026-09-02: 59% of volume sold short2026-09-03: 55% of volume sold short2026-09-04: 51% of volume sold short2026-09-08: 40% of volume sold short2026-09-09: 62% of volume sold short2026-09-10: 45% of volume sold short2026-09-11: 64% of volume sold short2026-09-14: 49% of volume sold short2026-09-15: 66% of volume sold short2026-09-16: 72% of volume sold short2026-09-17: 80% of volume sold short2026-09-18: 62% of volume sold short2026-09-21: 36% of volume sold short2026-09-22: 42% of volume sold short2026-09-23: 46% of volume sold short2026-09-24: 36% of volume sold short2026-09-25: 41% of volume sold short2026-09-28: 32% of volume sold short2026-09-29: 54% of volume sold short2026-09-30: 58% of volume sold short2026-10-01: 77% of volume sold short2026-10-02: 61% of volume sold short2026-10-05: 62% of volume sold short2026-10-06: 54% of volume sold short2026-10-07: 54% of volume sold short2026-10-08: 50% of volume sold short2026-10-09: 57% of volume sold short2026-10-12: 54% of volume sold short2026-10-13: 63% of volume sold short2026-10-14: 60% of volume sold short2026-10-15: 71% of volume sold short2026-10-16: 55% of volume sold short2026-10-19: 44% of volume sold short2026-10-20: 58% of volume sold short2026-10-21: 56% of volume sold short2026-10-22: 46% of volume sold short2026-10-23: 43% of volume sold short2026-10-26: 23% of volume sold short2026-10-27: 19% of volume sold short2026-10-28: 23% of volume sold short2026-10-29: 41% of volume sold short2026-10-30: 51% of volume sold short2026-11-02: 51% of volume sold short2026-11-03: 58% of volume sold short2026-11-04: 60% of volume sold short2026-11-05: 67% of volume sold short2026-11-06: 65% of volume sold short2026-11-09: 63% of volume sold short2026-11-10: 61% of volume sold short2026-11-11: 62% of volume sold short2026-11-12: 82% of volume sold short2026-11-13: 71% of volume sold short2026-11-16: 55% of volume sold short2026-11-17: 63% of volume sold short2026-11-18: 51% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 51%20-day average: 50%Prior 2 months: 54%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded DXCM

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Tina SmithSenate Sold $100,001 - $250,000 May 7, 2026May 10, 2026 +30.3%
Tina SmithSenate Sold $100,001 - $250,000 Apr 29, 2026May 10, 2026 +37.9%
John BoozmanSenate Bought $1,001 - $15,000 Jan 26, 2026Feb 15, 2026 +8.2%

What happened after DXCM insiders bought

Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.

Across all stocks →
FiledInsiderBought7 days30 days90 days
Nov 10, 2025Jacob Steven LeachCOO, President$1.0M +6.7%+9.0% vs S&P+23.2%+22.3% vs S&P+27.9%+25.8% vs S&P

Insiders at Dexcom

InsiderBoughtSoldLast filingPast buys beat S&PScore
Kevin R. SayerChair — $8.3M Aug 24, 2026 — —
Jacob Steven LeachCEO, President $1.0M — Nov 10, 2026 — —
Michael Jon BrownGeneral Counsel — $1.2M Nov 18, 2026 — —
Jon ColemanEvp, Chief Commercial Officer — $723K Jun 5, 2026 — —
Nicholas AugustinosDirector — $680K Sep 16, 2026 — —
Sadie SternEvp Chief People & Culture Off — $649K Nov 10, 2026 — —
Mark G. FolettaDirector — $627K Aug 4, 2026 0 of 1 —
Richard Alexander CollinsDirector — $389K Jun 1, 2026 — —
Jereme M. SylvainCFO, COO — $303K Nov 10, 2026 — —
Bridgette P. HellerDirector — $278K Aug 13, 2026 — —
Euan A. AshleyDirector — — Nov 3, 2026 — —
Glenn S. BoehnleinDirector — — Sep 10, 2026 — —
Renee D. GalaDirector — — Jun 1, 2026 — —
Rimma DriscollDirector — — Jun 1, 2026 — —
Albert Frederick Osterloh IVDirector — — Jun 1, 2026 — —
Kyle MaladyDirector — — Jun 1, 2026 — —
Steven R. AltmanDirector — — Jun 1, 2026 — —

Board links: companies that share insiders with DXCM

Directors and executives who filed Form 4s for DXCM and another company in the last 12 months.

See the map →
  • AAgilent Technologies Glenn S. Boehnlein Director here · Director at A · latest filing Sep 10, 2026
  • AMNAmn Healthcare Services Mark G. Foletta Director here · Director at AMN · latest filing Aug 4, 2026
  • JAZZJazz Pharmaceuticals Renee D. Gala Director here · CEO, President at JAZZ · latest filing Nov 5, 2026
  • SNESSenesTech Jacob Steven Leach CEO, President here · Director at SNES · latest filing Nov 10, 2026
  • VZVerizon Kyle Malady Director here · CEO at VZ · latest filing Nov 18, 2026
  • ZTSZoetis Rimma Driscoll Director here · President at ZTS · latest filing Jun 1, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

DXCM stock: common questions

Are Dexcom insiders buying DXCM stock?

No. No Dexcom insider reported an open-market purchase of DXCM in the past 12 months. The latest was COO, President Jacob Steven Leach bought $863K of DXCM at $54.98 — first open-market purchase in our records.

Are Dexcom insiders selling DXCM stock?

8 insiders reported sales worth $12.7M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is DXCM's P/E ratio?

DXCM trades at about 37.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is DXCM's 52-week range?

Over the past year DXCM has traded between $57.56 and $92.34. It last closed at $79.36 on Nov 19, 2026.